Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
HY209_SHAPERON Inc
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Sodium taurodeoxycholate for the treatment of sepsis...
Contact Yong U Kim
Participants
You
Email me a copy of this message

Anti-inflammation (GPCR131 agonist): Based on the novel theory we suggested in 2004 on Nature Reviews Immunology, we identified a novel compound (HY209) that can ameliorate inflammatory diseases such as sepsis, collagen-induced arthritis and atopic dermatitis. It activates GPCR131 pathway inducing Myeloid-derived suppressor cells and regulatory B cells that can suppress inflammatory responses. Because HY209 increases myeloid-derived suppressor cells and regulatory B cells in vivo, the indication might be expanded to various inflammatory diseases like Alzheimer’s disease.

Type of Business Relationship Sought

investment, research collaboration or technology licensing.

FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
GOVERNMENT INSTITUTE